Regulus Therapeutics Inc (NASDAQ:RGLS) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.87 and traded as high as $0.94. Regulus Therapeutics shares last traded at $0.80, with a volume of 5,500 shares changing hands.
A number of analysts have issued reports on RGLS shares. HC Wainwright started coverage on Regulus Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $2.00 target price on the stock. Wedbush reaffirmed a “hold” rating and issued a $1.00 target price on shares of Regulus Therapeutics in a report on Thursday, November 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a report on Tuesday, August 13th. Finally, Zacks Investment Research raised Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a report on Wednesday, November 20th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $1.31.
The stock has a market cap of $17.37 million, a price-to-earnings ratio of -0.14 and a beta of 1.55. The stock has a fifty day simple moving average of $0.68 and a 200-day simple moving average of $0.87.
Large investors have recently made changes to their positions in the company. NEA Management Company LLC lifted its position in shares of Regulus Therapeutics by 124.1% during the 2nd quarter. NEA Management Company LLC now owns 2,052,455 shares of the biopharmaceutical company’s stock worth $2,566,000 after buying an additional 1,136,704 shares during the period. EcoR1 Capital LLC bought a new position in shares of Regulus Therapeutics during the 2nd quarter worth approximately $1,389,000. Samsara BioCapital LLC bought a new position in shares of Regulus Therapeutics during the 2nd quarter worth approximately $1,131,000. Finally, CVI Holdings LLC bought a new position in shares of Regulus Therapeutics during the 2nd quarter worth approximately $568,000. 36.76% of the stock is currently owned by institutional investors.
About Regulus Therapeutics (NASDAQ:RGLS)
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Featured Article: High-Yield Dividend Stocks
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
